Tapping into China’s rising influence on drug development
China’s growing involvement in early-stage, out-licensing deals to global pharmaceutical partners is a healthy development for patients and investors alike, says Fidelity’s Eirene Kontopoulos.
-
A recent surge in high-value deals where Chinese biotechnology companies originate novel assets that are then licensed by Western pharmaceutical firms for global development and commercialization has fostered a more competitive, efficient and ultimately more productive environment for therapeutic innovation, with the potential to benefit patients and investors worldwide, according to Fidelity Portfolio Manager Eirene Kontopoulos.
-
“By licensing a promising, clinically validated asset from a Chinese partner, pharma and large biotechs can supplement their internal drug-development pipeline with greater capital efficiency,” says Kontopoulos, who manages Fidelity Advisor® Biotechnology Fund. “This allows them to allocate internal R&D funds toward higher-risk, frontier science, rather than just competing for the same domestic assets.”
-
In helming the industry-based, equity-focused strategy since 2018, Kontopoulos believes that successfully investing in biotechnology requires a competitive edge on the science behind the drugs, the likelihood of clinical success and the size of the total addressable market. She favors companies that can develop what she considers the most innovative therapies.
-
Kontopoulos has watched with interest as China’s influence has grown amid a shift away from the primary model in which Western innovation was licensed into China for local-market access: In 2024, about 30% of all assets in large pharma licensing deals came from China, a significant increase from 20% in 2023 and a very low level five years ago, she says.
-
“With more ‘shots on goal’ coming from multiple geographic locations, the probability of successfully bringing transformative medicines to market increases,” says Kontopoulos, who holds a doctorate in neuroscience from Harvard Medical School.
-
Sourcing assets from China has some noteworthy advantages, according to Kontopoulos, particularly in fast-evolving areas like antibody-drug conjugates, or ADCs, and cell therapies.
-
As an example, she cites the shorter timeline that can result from the operational speed and agility often demonstrated by Chinese biotechs in early-stage clinical development.
-
The significant success of Chinese-developed ADCs has created a rising tide that has lifted the entire field,” she explains, adding that it has attracted more investment, talent and research into the ADC space globally, leading to second- and third-generation advancements that otherwise might have taken longer to emerge.
-
One of the ways she has positioned the fund to potentially capitalize is through a stake in Summit Therapeutics. The Miami-based company has partnered with Chinese firm Akeso to license the former‘s breakthrough bispecific antibody, ivonescimab, according to Kontopoulos, who describes Akeso as a pioneer and source originator in developing innovative antibodies.
-
“The agreement supports Summit’s mission of developing and commercializing groundbreaking oncology pipeline products aimed at improving the quality of life of patients with a serious unmet medical need,” she says.
-
Larger drugmakers also are getting involved, with Kontopoulos pointing to Regeneron Pharmaceuticals’ licensing of an obesity-related asset from China, as well as AbbVie sourcing an oncology asset. AbbVie was the fund’s top holding as of September 30, at 19% of assets, whereas Regeneron was not held.
-
“This licensing of Chinese assets by global drug manufacturers is a trend that may have far-reaching implications – potentially accelerating the delivery of innovative therapies to market and boosting revenue for biopharma firms,” concludes Kontopoulos.
Fidelity Advisor Biotechnology Fund (FBTIX)
Seeks to provide capital appreciation.
Related insights
View all
For specific fund information such as standard performance and holdings, please go to the "Funds Managed" link on this page.
Investment decisions should be based on an individual’s own goals, time horizon, and tolerance for risk. Nothing in this content should be considered to be legal or tax advice, and you are encouraged to consult your own lawyer, accountant, or other advisor before making any financial decision. These materials are provided for informational purposes only and should not be used or construed as a recommendation of any security, sector, or investment strategy.
Fidelity does not provide legal or tax advice and the information provided herein is general in nature and should not be considered legal or tax advice. Consult with an attorney or a tax professional regarding your specific legal or tax situation.
Past performance and dividend rates are historical and do not guarantee future results.
Investing involves risk, including risk of loss.
Diversification does not ensure a profit or guarantee against loss.
Sector funds can be more volatile because of their narrow concentration in a specific industry. Growth stocks can perform differently from other types of stocks and the market as a whole and can be more volatile than other types of stocks. Value stocks can perform differently than other types of stocks and can continue to be undervalued by the market for long periods of time. • Stock markets, especially foreign markets, are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. • Foreign securities are subject to interest rate, currency exchange rate, economic, and political risks, all of which are magnified in emerging markets. • In general the bond market is volatile, and fixed income securities carry interest rate risk. (As interest rates rise, bond prices usually fall, and vice versa. This effect is usually more pronounced for longer-term securities.) Fixed income securities also carry inflation, credit, and default risks for both issuers and counterparties. • Lower-quality bonds can be more volatile and have greater risk of default than higher-quality bonds. • Floating-rate loans may not be fully collateralized and therefore may decline significantly in value. • The municipal market is volatile and can be significantly affected by adverse tax, legislative, or political changes, and the financial condition of the issuers of municipal securities. • The securities of smaller, less well-known companies can be more volatile than those of larger companies. • The funds can invest in securities that may have a leveraging effect (such as derivatives and forward-settling securities) that may increase market exposure, magnify investment risks, and cause losses to be realized more quickly. • Leverage can magnify the impact of adverse issuer, political, regulatory, market, or economic developments on a company. In the event of bankruptcy, a company’s creditors take precedence over the company’s stockholders. Although the companies that the fund invests in may be highly leveraged, the fund itself does not use leverage as an investment strategy. Changes in real estate values or economic downturns can have a significant negative effect on issuers in the real estate industry. In the event of bankruptcy, a company’s creditors take precedence over the company’s stockholders. Third-party marks are the property of their respective owners; all other marks are the property of FMR LLC.